AI screening for cardiac amyloidosis, a rare, underdiagnosed, and now-treatable disease, from routine transthoracic echocardiography. Integrates information across apical-4-chamber and parasternal-long-axis view videos to assess amyloid-associated features holistically. Developed with support from Alexion, AstraZeneca Rare Disease.
Product typeDiagnostics & Imaging
Pricing ·
Deployment
APINot available
What teams use Precision Cardiac Amyloid for
Automated echocardiographic LVEF measurement
AI screening for cardiac amyloidosis
Opportunistic liver disease screening from echocardiography